The Princeton, New Jersey-based group is to sell 10mln shares at a price of US$2, a 20% discount to Wednesday’s closing price of of US$2.51.
Advaxis has also granted the underwriters a 30-day option to buy up to a further 807,697 shares at the same price which would bring in another US$1.6mln or so.
The money will be used to fund its various research and development programmes, including its lead product, Axalimogene Filolisbac, for which it submitted a European marketing application last week.
That application was for use as a second-line treatment in women with recurrent or metastatic cervical cancer but Advaxis is also looking to develop the drug for use in other cancer indications and possibly as one part of a combination therapy.
Advaxis shares fell 26.1% to US$1.85 - taking them below the offer price.